Skip to content

Study · Non-randomized trial · 2008

4 results

A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration.

Muresanu DF, Alvarez XA, Moessler H, Buia M, Stan A, Pintea D, Moldovan F, Popescu BO

Journal of the neurological sciences28 Nov 2007Cited by 31 (Europe PMC)

PMID18048059 (opens in a new tab)DOI10.1016/j.jns.2007.10.016 (opens in a new tab)PepBankPUB-18048059
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In vascular dementia patients, Cerebrolysin at 10 ml significantly improved cognitive performance in the placebo-controlled study.

    In plain wordsIn vascular dementia patients, Cerebrolysin at 10 ml improved cognitive performance in a study with placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseADAS-cog cognitive performance
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 ml · i.v. infusions · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Cere treatment improved cognitive performance significantly at the 10 ml dose and reduced EEG slowing with both 10 and 30 ml dosages.
    3 context sentences
    Summary · context
    The effects of the neurotrophic compound Cerebrolysin (Cere) on cognitive performance, evaluated with the ADAS-cog, and on qEEG activity were investigated in forty one patients with mild to moderate severe probable vascular dementia (VaD) according to NINDS-AIREN criteria, included in a placebo-controlled pilot study.
    Summary · context
    Patients received i.v. infusions of Cere (10 or 30 ml) or placebo (normal saline) 5 days/week for 4 weeks.
    Summary · context
    Mean score of change from baseline in the ADAS-cog and percent change from baseline in slow to fast EEG power ratio (PR) scores were the two primary endpoints.
  2. 02HumanNon-randomized trialEfficacy outcome

    In vascular dementia patients, Cerebrolysin at 10 ml reduced EEG slowing in the placebo-controlled study.

    In plain wordsIn vascular dementia patients, Cerebrolysin at 10 ml reduced EEG slowing in a study with placebo.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEEG slowing
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml · i.v. infusions · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Cere treatment improved cognitive performance significantly at the 10 ml dose and reduced EEG slowing with both 10 and 30 ml dosages.
    3 context sentences
    Summary · context
    The effects of the neurotrophic compound Cerebrolysin (Cere) on cognitive performance, evaluated with the ADAS-cog, and on qEEG activity were investigated in forty one patients with mild to moderate severe probable vascular dementia (VaD) according to NINDS-AIREN criteria, included in a placebo-controlled pilot study.
    Summary · context
    Patients received i.v. infusions of Cere (10 or 30 ml) or placebo (normal saline) 5 days/week for 4 weeks.
    Summary · context
    Mean score of change from baseline in the ADAS-cog and percent change from baseline in slow to fast EEG power ratio (PR) scores were the two primary endpoints.
  3. 03HumanNon-randomized trialEfficacy outcome

    In vascular dementia patients, Cerebrolysin at 30 ml reduced EEG slowing in the placebo-controlled study.

    In plain wordsIn vascular dementia patients, Cerebrolysin at 30 ml reduced EEG slowing in a study with placebo.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEEG slowing
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml · i.v. infusions · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Cere treatment improved cognitive performance significantly at the 10 ml dose and reduced EEG slowing with both 10 and 30 ml dosages.
    3 context sentences
    Summary · context
    The effects of the neurotrophic compound Cerebrolysin (Cere) on cognitive performance, evaluated with the ADAS-cog, and on qEEG activity were investigated in forty one patients with mild to moderate severe probable vascular dementia (VaD) according to NINDS-AIREN criteria, included in a placebo-controlled pilot study.
    Summary · context
    Patients received i.v. infusions of Cere (10 or 30 ml) or placebo (normal saline) 5 days/week for 4 weeks.
    Summary · context
    Mean score of change from baseline in the ADAS-cog and percent change from baseline in slow to fast EEG power ratio (PR) scores were the two primary endpoints.
  4. 04HumanNon-randomized trialMechanism

    In Cerebrolysin-treated vascular dementia patients, changes in EEG power ratio and ADAS-cog scores showed a significant positive correlation.

    In plain wordsIn vascular dementia patients given Cerebrolysin, changes in EEG power ratio were linked positively to changes in cognitive scores.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableCorrelation of EEG power ratio and ADAS-cog changes
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 or 30 ml · i.v. infusions · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    A significant positive correlation between PR and ADAS-cog scores of change from baseline was observed in Cere-treated patients.
    1 context sentence
    Summary · context
    Patients received i.v. infusions of Cere (10 or 30 ml) or placebo (normal saline) 5 days/week for 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.